Can a patient with a benign uterus ≤12‑week gestational size, no suspected malignancy or extensive pelvic adhesions, no severe bowel or bladder endometriosis, and a body mass index ≤35 kg/m² undergo vaginal natural orifice transluminal endoscopic surgery (VNOTES) hysterectomy?

VNOTES Hysterectomy for Benign Enlarged Uterus

Yes, a patient meeting these criteria can safely undergo VNOTES hysterectomy, as this represents an appropriate candidate for minimally invasive vaginal surgery based on established evidence supporting vaginal approaches for uteri up to 12-week size.

Evidence-Based Rationale

The patient profile described—benign uterus ≤12-week gestational size, no malignancy, no extensive adhesions, no severe bowel/bladder endometriosis, and BMI ≤35 kg/m²—represents an ideal candidate for vaginal natural orifice surgery. While the provided guidelines don't specifically address VNOTES (a newer technique), they strongly support minimally invasive and vaginal approaches for similar clinical scenarios.

Supporting Evidence from Guidelines

Minimally invasive surgery is strongly recommended for benign gynecologic conditions 1. The ESMO-ESGO-ESTRO consensus explicitly states that vaginal hysterectomy with salpingo-oophorectomy can be considered in selected patients with low-risk conditions 1. The 2000 guideline data, while older, established that vaginal hysterectomy showed no disadvantage compared to laparoscopically assisted approaches, and laparoscopic assistance was advantageous over abdominal hysterectomy for uteri 12-18 weeks in size 2.

Research Evidence Confirms Safety

Multiple research studies demonstrate the feasibility and safety of vaginal approaches for enlarged uteri:

• Vaginal hysterectomy for uteri 14-20 weeks gestational size was successfully completed in all cases with mean operating time of 84.3 minutes, minimal complications (transient hematuria and superficial vaginal grazes), and mean hospital stay of 3.7 days 3

• Vaginal hysterectomy for enlarged uteri (mean 16.3 weeks, range 14-20 weeks) with uterine weights 380-1100g showed excellent outcomes using bisection, myomectomy, and morcellation techniques 3

• Larger uteri up to 1244 ml volume were safely managed vaginally with mean operation time of 159.7 minutes and mean hospital stay of 3.79 days 4

Clinical Algorithm for VNOTES Candidacy

Your patient meets all favorable criteria:

✓ Uterine size ≤12 weeks (well within safe range; evidence supports up to 20 weeks vaginally)
✓ Benign pathology confirmed (no malignancy concern)
✓ No extensive pelvic adhesions (allows adequate vaginal access and mobilization)
✓ No severe bowel/bladder endometriosis (avoids risk of inadvertent organ injury)
✓ BMI ≤35 kg/m² (facilitates vaginal access and reduces operative complexity)

Key Advantages Over Abdominal Approach

Vaginal approaches consistently demonstrate superior outcomes:

• Shorter hospital stays (2-4 days vs. longer with abdominal)
• Faster return to normal activities
• Lower infection rates
• Less postoperative pain
• Better quality of life scores 5, 3

Critical Caveats and Pitfalls

Preoperative assessment must exclude malignancy. The incidence of unexpected uterine malignancies in benign hysterectomies is 0.33% (0.26% endometrial carcinoma, 0.08% uterine sarcoma) 6. Ensure adequate endometrial sampling and imaging before proceeding.

Surgeon experience is paramount. Success with VNOTES for enlarged uteri requires expertise in vaginal surgery techniques including bisection, myomectomy, and morcellation 3. If the surgeon lacks this experience, referral to a specialist in vaginal surgery is appropriate.

Intraoperative flexibility is essential. Have preparations for conversion to laparoscopy or laparotomy if unexpected findings occur (severe adhesions, inability to deliver uterus, hemorrhage). However, conversion rates should be low (<5%) with proper patient selection 7.

Contained morcellation if needed. If uterine size requires morcellation, use in-bag techniques to minimize tissue dissemination risk, though this is less concerning with confirmed benign pathology 6.

Contraindications That Would Exclude VNOTES

Do NOT proceed with VNOTES if:

• Suspected malignancy (requires staging and intact specimen removal)
• Uterine size >12-14 weeks without advanced vaginal surgery expertise
• Severe pelvic adhesions limiting vaginal access
• Deep infiltrating endometriosis involving bowel/bladder requiring en-bloc resection
• BMI >35 kg/m² (relative contraindication; assess vaginal access)
• Nulliparity with very narrow vaginal caliber (relative contraindication)

The described patient represents an optimal candidate for VNOTES hysterectomy, combining the benefits of minimally invasive surgery with vaginal approach advantages, provided the surgeon has appropriate expertise in advanced vaginal surgical techniques.